Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Mol Cancer Res. 2011 May 2;9(6):724–732. doi: 10.1158/1541-7786.MCR-10-0436

FIGURE 4. TNK1 is an Achilles’ Heel target in pancreatic cancer cells.

FIGURE 4

A, BxPC3, MiaPaCa-2, AsPC-1, Panc-1, and Su.86.86 cells were treated with three different siRNA sequences targeting TNK1, a Non-silencing control siRNA and a positive control lethal siRNA (not shown). At 96 hours post transfection, cell viability was measured using Cell Titer Glo and expressed as percent of control. B, BxPC3 cells were incubated with TNK1 siRNA or non-silencing control for 24, 48, and 72 hours. Lethal control siRNA was also included (not shown). Apoptotic activity was measured using Caspase-Glo 3/7 reagent. Increased readout indicates an increase in Caspase 3/7 activity. Student’s t-test were completed for statistical analysis (relative to non-silencing control), *p<0.05. C, Whole cell lysates were immunoprecipitated using a bead-bound p-Tyr antibody and analyzed by western blot. A blot for EGFR (a commonly phosphorylated tyrosine kinase) was included as a positive control for the immunoprecipitation. Final images were cropped to highlight relevant bands.